- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00991302
Durability of Adherence in Self-Management of HIV (DASH)
Visão geral do estudo
Descrição detalhada
People infected with HIV must take the regimen of highly active antiretroviral therapy (HAART) medications as prescribed to them, without missing doses, or they risk developing a resistant strain of the virus. Resistant strains of the virus do not respond to certain HAART regimens and are more dangerous for patients. Poor HAART adherence can lead to further HIV progression, more hospitalizations and opportunistic infections, and required use of second-line therapies. Interventions to increase adherence have had mixed success, with little data to support long-term effects and no one strategy emerging that provides consistent positive effects. The client adherence profiling and intervention tailoring (CAP-IT) program was first developed to increase adherence among people already on HAART with in-home nursing. This study modified CAP-IT to treat people newly on HAART and then tested whether this modified CAP-IT improved long-term HAART adherence.
This study included two stages. The first stage consisted of two focus groups, one made up of HIV care providers and professionals and the other made up of people infected with HIV who had started HAART within the last year. Each focus group met once, for approximately 2 hours, to determine what modifications would best adapt the CAP-IT program to HIV-infected people first starting HAART.
The second stage consisted of a randomized trial comparing the modified CAP-IT program to standard of care. Participation in this stage lasted for 72 weeks. Participants were randomly assigned to receive either standard care or the modified CAP-IT program in addition to standard care. The CAP-IT program involved two steps. The first was an assessment of factors relating to adherence, and the second was development of an individualized plan to address the deficits found.
Study visits were completed at entry, at Weeks 4 and 12, and then every 12 weeks for approximately 72 weeks. Assessments for the study included a questionnaire about health attitudes, a physical exam, counting of pills, and answering questions about taking medications.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
California
-
San Diego, California, Estados Unidos, 92037
- Ucsd, Avrc Crs
-
-
-
-
-
Lima, Peru, 18 PE
- Barranco CRS (11301)
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
Stage 1
HIV infected Individuals on Highly Active Antiretroviral Therapy (HAART):
- HIV-1 infection
- Initiated HAART within 1 year prior to study entry and remained on HAART for at least 30 consecutive days
- Men and women who hade reached the legal age of majority in the country where they are being enrolled
- Ability and willingness to provide informed consent
- Willingness to discuss personal topics during an audio-taped group interview
- Willingness to protect the confidentiality of other focus group participants
Health Care Providers and Professionals:
- Healthcare providers or professionals (e.g., medical doctors [MDs], nurse practitioner [NPs], physician assistants [PAs], adherence counselors) recruited from outside of the local clinical research site (CRS) whose patient population included a majority of HIV-1 seropositive patients and who had recent experience managing ART-naive individuals starting HAART
- Men and women who had reached the legal age of majority in the country where they are being enrolled
- Willingness to discuss personal topics during an audio-taped group interview
- Willingness to protect the confidentiality of other focus group participants and of the proceedings
Stage 2:
- HIV-1 infection
- Antiretroviral (ARV) treatment naive, but planning to initiate HAART within 7 days of study entry either in the context of an approved parent AIDS Clinical Trial Group (ACTG) clinical trial or in the context of primary HIV care at a University of California, San Diego (UCSD), USA or Asociacion Civil Impacta Salud Y Educaci (IMPACTA), Peru, CRS-affiliated site
- HIV-1 RNA greater than 1,000 copies/mL obtained within 90 days prior to study entry by any laboratory that has a clinical laboratory improvement amendments (CLIA) certification or its equivalent
- CD4+/CD8+ count obtained within 90 days prior to study entry by any laboratory that has a CLIA certification or its equivalent
- Men and women who had reached the legal age of majority in the country where they are being enrolled
- Ability to follow instructions and complete surveys and questionnaires with minimal assistance
Exclusion Criteria:
Stage 1
HIV-1 Infected Individuals on HAART:
- Failure to remain on HAART for at least 30 consecutive days
- Diminished cognitive capacity that, in the opinion of the screening CRS clinician, would interfere with study participation
- Participation in any prior focus group for study A5250
Health Care Providers and Professionals:
- Health care providers and professionals who would be involved in administering standard of care (SOC) treatment and adherence counseling to Stage 2 participants randomized to the SOC arm or CRS investigators or health care providers and professionals directly involved in measuring adherence outcomes in Stage 2
- Participation in any prior focus group for study A5250
Stage 2:
- Potential participants who were, in the judgment of the research team, unable to complete the protocol
- Potential participants who were starting a NNRTI-based regimen within 12 months after receiving single-dose NVP during pregnancy to prevent MTCT of HIV
- Potential participants who were partners or close contacts of participants enrolled in Stage 2
- Potential participants who were currently enrolled in an ACTG protocol utilizing or testing an adherence intervention
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: CAP-IT
Participants received the modified CAP-IT adherence intervention in addition to standard care. Modified client adherence profiling and intervention tailoring (CAP-IT): Interventions designed to improve medication adherence, modified to specifically target people first starting highly active antiretroviral therapy (HAART) |
Interventions designed to improve medication adherence, modified to specifically target people first starting highly active antiretroviral therapy (HAART)
Outros nomes:
|
Sem intervenção: Standard care
Participants received standard care.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Mean Self-reported Adherence Score (%) Over a One-month Recall
Prazo: At weeks 4, 12, 24, 36, and 48
|
The adherence self-report questionnaire captured adherence at an Antiretroviral Therapy (ART) regimen over a one-month recall (0-100): 0 means none of anti-HIV medications were taken, 100 means every single dose of anti-HIV medications were taken. The primary endpoint evaluated for each participant was the average self-reported adherence over a one-month recall across each of their study visit week 4, 12, 24, 36, and 48: missing values were ignored. Note: This was a change to the primary endpoint as described in the study protocol. This was due to an update to ACTG Case Report Form (CRF) that captured self-report adherence. Since the data captured on this form captured adherence over a longer timeframe and allowed for more variability in response, it was anticipated this endpoint would provide greater power to assess treatment differences. |
At weeks 4, 12, 24, 36, and 48
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Mean Self-reported Adherence Score Over a One-month Recall
Prazo: Weeks 4, 12, 24, 36, 48, 60, and 72
|
The mean of participant's average self-reported adherence score over a one-month recall across visit week 4, 12, 24, 36, 48, 60, and 72; missing values were ignored.
|
Weeks 4, 12, 24, 36, 48, 60, and 72
|
Kaplan-Meier Estimate of the Cumulative Probability of Time to Change of Initial Antiretroviral (ARV) Treatment Regimen for Any Reason by Week 48
Prazo: From study entry to week 48
|
The Kaplan-Meier estimate of the cumulative probability of initial antiretroviral (ARV) treatment regimen for any reason by week 48. Time to ARV treatment regimen change was defined as first time to change in the drug class of participant's ART regimen for any reason from study entry. Participants completing the study without a change in the drug class of their ART regimen were censored at their last visit. |
From study entry to week 48
|
Virologic Suppression
Prazo: At week 24, 48, 72
|
Virologic suppression was defined as HIV-1 RNA <=200 copies/mL at week 24, 48, and 72.
The results obtained within +/- 12 weeks of 24, 48, and 72 weeks were included.
If there were multiple HIV-1 RNA measurement within the specified window, the HIV-1 RNA result closest to the center of the window was selected.
|
At week 24, 48, 72
|
Self-management Skills, as Measured by Self-reported General Self-efficacy Scale (GSES) Score
Prazo: At weeks 0 (entry), 4, 12, 24, 36, 48, 60, and 72
|
The GSES is a 10-item scale designed to assess optimistic self-beliefs used to cope with a variety of demands in life. The scale was designed to assess self efficacy, i.e., the belief that one's actions are responsible for successful outcomes. The scaled score for each question ranges from 1 to 4. Higher scores indicate participant's stronger belief in self-efficacy. The GSES score was sum of all responses. The range was from 0 to 40 scores: any unfinished question got a score of zero. |
At weeks 0 (entry), 4, 12, 24, 36, 48, 60, and 72
|
Cumulative Probability of First Grade 3 or 4 Adverse Events (AEs)
Prazo: From study entry to week 72
|
The Kaplan-Meier estimate of the cumulative probability of experiencing a grade 3 or 4 adverse event by week 72. New Grade 3 or 4 signs, symptoms were identified by MedDRA preferred term. Events were included regardless of participant status on ART. If a participant had multiple reports of the same event, only the event reported at the highest grade were included. Time was measured from the study entry until the date of the first new grade 3 or 4 adverse event. Participants lost to follow-up prior to reaching an adverse event endpoint or not documented to have reached an adverse event endpoint at the end of the study had their endpoint censored at the date of their last visit. |
From study entry to week 72
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Cadeira de estudo: Constance Benson, MD, University of California, San Diego
- Cadeira de estudo: Tari Gilbert, MSN, University of California, San Diego
Publicações e links úteis
Publicações Gerais
- Lu M, Safren SA, Skolnik PR, Rogers WH, Coady W, Hardy H, Wilson IB. Optimal recall period and response task for self-reported HIV medication adherence. AIDS Behav. 2008 Jan;12(1):86-94. doi: 10.1007/s10461-007-9261-4. Epub 2007 Jun 19.
- Wagner GJ, Kanouse DE, Golinelli D, Miller LG, Daar ES, Witt MD, Diamond C, Tilles JG, Kemper CA, Larsen R, Goicoechea M, Haubrich RH. Cognitive-behavioral intervention to enhance adherence to antiretroviral therapy: a randomized controlled trial (CCTG 578). AIDS. 2006 Jun 12;20(9):1295-302. doi: 10.1097/01.aids.0000232238.28415.d2.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Infecções por vírus de RNA
- Doenças Virais
- Infecções
- Infecções transmitidas pelo sangue
- Doenças Transmissíveis
- Doenças Sexualmente Transmissíveis, Virais
- Doenças Sexualmente Transmissíveis
- Infecções por Lentivírus
- Infecções por Retroviridae
- Síndromes de Deficiência Imunológica
- Doenças do sistema imunológico
- Infecções por HIV
Outros números de identificação do estudo
- ACTG A5250
- 1U01AI068636 (Concessão/Contrato do NIH dos EUA)
- 10654
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Infecções por HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecrutamentoHIV | Teste de HIV | Ligação do HIV ao Cuidado | Tratamento de HIVEstados Unidos
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement e outros colaboradoresDesconhecidoHIV | Crianças não infectadas pelo HIV | Crianças expostas ao HIVCamarões
-
University of MinnesotaRetiradoInfecções por HIV | HIV/AIDS | HIV | AUXILIA | Aids/problema de HIV | AIDS e InfecçõesEstados Unidos
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationConcluídoTeste de HIV do parceiro | Aconselhamento de casal HIV | Comunicação de casal | Incidência de HIVCamarões, República Dominicana, Geórgia, Índia
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... e outros colaboradoresRecrutamentoHIV | Teste de HIV | Vinculação ao cuidadoÁfrica do Sul
-
CDC FoundationGilead SciencesDesconhecidoProfilaxia pré-exposição ao HIV | Quimioprofilaxia HIVEstados Unidos
-
Erasmus Medical CenterAinda não está recrutandoInfecções por HIV | HIV | Infecção por HIV-1 | Infecção HIV IHolanda
-
National Taiwan UniversityRecrutamento
-
Helios SaludViiV HealthcareDesconhecidoHIV | Infecção por HIV-1Argentina
-
University of Maryland, BaltimoreRetiradoHIV | Transplante de rim | Reservatório de HIV | CCR5Estados Unidos
Ensaios clínicos em CAP-IT
-
Philips Clinical & Medical Affairs GlobalConcluídoDoença na artéria periférica | Isquemia Crítica de MembroÁustria
-
Oslo University HospitalCentre for Appearance Research, University of the West of England, UKInscrevendo-se por conviteQueimaduras | Fissura Lábio-Palatal | Anormalidades Craniofaciais | Condição de pele | Outras condições que levam a uma diferença visívelNoruega
-
Integro TheranosticsRecrutamentoCâncer de mama | CDIS | Carcinoma ductal invasivo da mamaEstados Unidos
-
ShireConcluídoSíndrome de HunterEstados Unidos, Reino Unido
-
Capricor Inc.ConcluídoDistrofia Muscular de DuchenneEstados Unidos
-
Capricor Inc.ConcluídoDistrofia Muscular de Duchenne | CardiomiopatiaEstados Unidos
-
Liverpool School of Tropical MedicineKenya Medical Research Institute; LVCT HealthAinda não está recrutandoGravidez | Sistemas de Saúde | Sistemas Eletrônicos de Informação em Saúde Comunitária | Captação da clínica pré-natal
-
University of Alabama at BirminghamRecrutamentoDemência | Comportamento resistente ao cuidadoEstados Unidos
-
Oregon Health and Science UniversityTexas A&M University; University of North Carolina, GreensboroAtivo, não recrutandoAtividade físicaEstados Unidos